{"id":11196,"date":"2021-03-18T00:00:00","date_gmt":"2021-03-18T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/"},"modified":"2025-08-19T08:28:17","modified_gmt":"2025-08-19T13:28:17","slug":"excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/","title":{"rendered":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY"},"content":{"rendered":"<p>Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie cellulaire, la premi\u00e8re en son genre dans le monde. Le projet <em>ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation<\/em> est une collaboration entre l\u2019Universit\u00e9 Queen\u2019s, l\u2019Universit\u00e9 McMaster, l\u2019Universit\u00e9 de Calgary, l\u2019Universit\u00e9 d\u2019Ottawa, l\u2019Universit\u00e9 de Montr\u00e9al, et la Soci\u00e9t\u00e9 canadienne du sang. Les fonds de la FCI appuieront les activit\u00e9s de recherche du d\u00e9veloppement de th\u00e9rapies cellulaires novatrices \u00e0 la fabrication de cellules au point de service et un essai clinique multicentrique pour le traitement du cancer. Ce projet vise \u00e0 d\u00e9velopper des th\u00e9rapies cellulaires comme options de traitement s\u00e9curitaires et viables en identifiant les m\u00e9canismes biologiques qui nuisent \u00e0 l\u2019innocuit\u00e9 et \u00e0 concevoir des m\u00e9thodes rentables pour le pr\u00e9l\u00e8vement, l\u2019expansion, la manipulation, la purification, et le transport de cellules.<\/p>\n<p>Consultez les articles ci-dessous pour en savoir plus (disponible en anglais seulement)&nbsp;:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.thewhig.com\/news\/local-news\/locally-led-cancer-research-project-receives-5-1-million-from-feds\" target=\"_blank\" rel=\"noopener\">Locally led cancer research project receives $5.1 million from feds<\/a><\/li>\n<li>\n<p><a href=\"https:\/\/www.queensu.ca\/gazette\/stories\/cfi-funds-queen-s-researchers-their-pursuits-exploration-and-discovery\" target=\"_blank\" rel=\"noopener\">Canada Foundation for Innovation funds Queen\u2019s researchers in their pursuits of exploration and discovery<\/a><\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11196","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2021-03-18T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:17+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#blogposting\",\"name\":\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\\u00c9 PAR ANNETTE HAY | My\\u00e9lome Canada\",\"headline\":\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\\u00c9 PAR ANNETTE HAY\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2021-03-18T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:17-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#listItem\",\"name\":\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\\u00c9 PAR ANNETTE HAY\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#listItem\",\"position\":4,\"name\":\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\\u00c9 PAR ANNETTE HAY\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/\",\"name\":\"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\\u00c9 PAR ANNETTE HAY | My\\u00e9lome Canada\",\"description\":\"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\\u00e9decine) chercheuse de l\\u2019Universit\\u00e9 Queen\\u2019s et Jonathan Bramson de l\\u2019Universit\\u00e9 McMaster, ont re\\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\\u2019innovation (FCI) pour leur projet visant \\u00e0 d\\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\\u00e9rapie\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/03\\\/18\\\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2021-03-18T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:17-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada","description":"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie","canonical_url":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#blogposting","name":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada","headline":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2021-03-18T00:00:00-05:00","dateModified":"2025-08-19T08:28:17-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#listItem","name":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#listItem","position":4,"name":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/","name":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada","description":"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2021-03-18T00:00:00-05:00","dateModified":"2025-08-19T08:28:17-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada","og:description":"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie","og:url":"https:\/\/myeloma.ca\/fr\/2021\/03\/18\/excellentes-nouvelles-pour-le-projet-excellirate-canada-expanding-cell-based-immunotherapy-research-acceleration-for-translation-and-evaluation-co-dirige-par-annette-hay\/","article:published_time":"2021-03-18T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:17+00:00","twitter:card":"summary_large_image","twitter:title":"EXCELLENTES NOUVELLES POUR LE PROJET EXCELLIRATE CANADA: EXPANDING CELL-BASED IMMUNOTHERAPY RESEARCH ACCELERATION FOR TRANSLATION AND EVALUATION, CO-DIRIG\u00c9 PAR ANNETTE HAY | My\u00e9lome Canada","twitter:description":"Le Groupe canadien des essais sur le cancer (GECC), Annette Hay (m\u00e9decine) chercheuse de l\u2019Universit\u00e9 Queen\u2019s et Jonathan Bramson de l\u2019Universit\u00e9 McMaster, ont re\u00e7u un financement de plus de 5 millions de dollars de la Fondation canadienne pour l\u2019innovation (FCI) pour leur projet visant \u00e0 d\u00e9velopper une plateforme nationale de recherche translationnelle sur la th\u00e9rapie"},"aioseo_meta_data":{"post_id":"11196","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 16:59:25","updated":"2026-04-30 07:19:04","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11196"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11196\/revisions"}],"predecessor-version":[{"id":31300,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11196\/revisions\/31300"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}